Evaluation of acute tacrine treatment on passive-avoidance response, open-field behavior, and toxicity in 17- and 30-day-old mice

Pharmacology Biochemistry and Behavior

Volumn 85, Issue 1, 2006, Pages 50-56

  Pan, S Y ^a   Han, Y F ^b   Yu, Z L ^c   Yang, R ^a   Dong, H ^a   Ko, K M ^b  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^c HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Acute toxicity; Defecation; Developmental changes; Hepatotoxicity; Locomotor; Open field memory; Passive avoidance response; Tacrine

Indexed keywords

ALANINE AMINOTRANSFERASE; TACRINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVITY; EVALUATION; IC 50; LATENT PERIOD; LIVER TOXICITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL;

ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; DEFECATION; DRUG EVALUATION, PRECLINICAL; LIVER; MALE; MICE; MICE, INBRED ICR; TACRINE;

EID: 33751092266     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.07.006     Document Type: Article

References (43)

1. Balduini W., Murphy S.D., and Costa L.G. Characterization of cholinergic muscarinic receptor-stimulated phosphoinositide metabolism in brain from immature rats. J Pharmacol Exp Ther 253 (1990) 573-579
2. Balduini W., Murphy S.D., and Costa L.G. Developmental changes in muscarinic receptor-stimulated phosphoinositide metabolism in rat brain. J Pharmacol Exp Ther 241 (1987) 421-427
3. Baskin D.S., Browning J.L., Pirozzolo F.J., Korporaal S., Baskin J.A., and Appel S.H. Brain choline acetyltransferase and mental function in Alzheimer disease. Arch Neurol 56 (1999) 1121-1123
4. Berger-Sweeney J. The effects of neonatal basal forebrain lesions on cognition: towards understanding the developmental role of the cholinergic basal forebrain. Int J Dev Neurosci 16 (1998) 603-612
5. Braida D., Paladini E., Griffini P., Lamperti M., Maggi A., and Sala M. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol 302 (1996) 13-20
6. Clarke P.B., and El-Bizri H.R.M. Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum. Br J Pharmacol 111 (1994) 695-702
7. Daws L.C., and Overstreet D.H. Ontogeny of muscarinic cholinergic supersensitivity in the Flinders Sensitive Line rat. Pharmacol Biochem Behav 62 (1999) 367-380
8. Diez-Ariza M., Redondo C., Garcia-Alloza M., Lasheras B., Del Rio J., and Ramirez M.J. Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats. Psychopharmacology (Berl) 169 (2003) 35-41
9. Freeman S.E., and Dawson R.M. Tacrine: a pharmacological review. Prog Neurobiol 36 (1991) 257-277
10. Hodges H., Ribeiro A.M., Gray J.A., and Marchbanks R.M. Low dose tetrahydroaminoacridine (THA) improves cognitive function but does not affect brain acetylcholine in rats. Pharmacol Biochem Behav 36 (1990) 291-298
11. Miranda M.I., Ferreira G., Ramirez-Lugo L., and Bermudez-Rattoni F. Role of cholinergic system on the construction of memories: taste memory encoding. Neurobiol Learn Mem 80 (2003) 211-222
12. Marighetto A., Touzani K., Etchamendy N., Torrea C.C., De Nanteuil G., Guez D., et al. Further evidence for a dissociation between different forms of mnemonic expressions in a mouse model of age-related cognitive decline: effects of tacrine and S 17092, a novel prolyl endopeptidase inhibitor. Learn Mem 7 (2000) 159-169
13. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. Learn Mem 11 (2004) 43-49
14. Nakahara N., Iga Y., Mizobe F., and Kawanishi G. Amelioration of experimental amnesia (passive avoidance failure) in rodents by selective M1 agonists AF102B. Jpn J Pharmacol 48 (1988) 502-506
15. Newhouse P.A., Potter A., Corwin J., and Lenox R. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology (Berl) 108 (1992) 480-484
16. O'Hara B.F., Macdonald E., Clegg D., Wiler S.W., Andretic R., Cao V.H., et al. Developmental changes in nicotinic receptor mRNAs and responses to nicotinic in the suprachiasmatic nucleus and other brain regions. Brain Res Mol Brain Res 66 (1999) 71-82
17. Oliver Jr. K., Liu J., and Pope C.N. Inhibition of forskolin-stimulated camp formation in vitro by paraoxon and chlorpyrifos oxon in cortical slices from neonatal, juvenile, and adults. J Biochem Mol Toxicol 15 (2001) 263-269
18. Ou L.Y., Tang X.C., and Cai J.X. Effect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys. Eur J Pharmacol 433 (2001) 151-156
19. Paddle B.M., and Dowling M.H. Blockade of cardiac nicotinic responses by anticholinesterases. Gen Pharmacol 27 (1996) 861-872
20. Pan S.Y., Han Y.F., Xu Q.P., Liu M.Y., Ma H.Z., Ding W.J., et al. Belladonna alkaloids-induced behavioral changes and amnesia on open-field and step-through in 18-, 28-, and 38-day-old mice. Acta Pharmacol Sin 19 (1998) 112-116
21. Pan S.Y., and Han Y.F. Learning deficits induced by 4 belladonna alkaloids are preferentially attenuated by tacrine. Acta Pharmacol. Sin 21 (2000) 124-130
22. Pan S.Y. Circadian effects of scopolamine on memory, exploratory behavior, and muscarinic receptors in mouse brain. Acta Pharmacol Sin 13 (1992) 323-326
23. Pan S.Y. Features of memory on novel situation and avoidance response: evidence from comparisons between open-field behavior and step-through task. Acta Pharmacol Sin 16 (1995) 125-129
24. Pan S.Y., and Han Y.F. Comparisons in the inhibitory efficacy of four belladonna drugs on gastrointestinal movement and cognitive function in food deprived mice. Pharmacology 72 (2004) 177-183
25. Pan S.Y., Han Y.F., Carlier P.R., Pang Y.P., Mak D.H.F., Lam B.Y.H., et al. Schisandrin B protects against tacrine- and bis(7)-tacrine-induced hepatotoxicity and enhances cognitive function in mice. Planta Med 68 (2002) 217-220
26. Pearce B.D., and Potter L.T. Effects of tetrahydroaminoacridine on M1 and M2 muscarinic receptors. Neurosci Lett 88 (1988) 281-285
27. Potamianos G., and Kellett J.M. Anti-cholinergic drugs and memory: the effects of benzhexol on memory in a group of geriatric patients. Br J Psychiatry 140 (1982) 470-472
28. Qizilbash N., Whitehead A., Higgins J., Wilcock G., Schneider L., and Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia trialists' collaboration. JAMA 280 (1998) 1777-1782
29. Riekkinen Jr. P., Sirvio J., Riekkinen M., and Riekkinen P. Effects of THA on passive avoidance retention performance of intact, nucleus basalis, frontal cortex and nucleus basalis + frontal cortex-lesioned rats. Pharmacol Biochem Behav 39 (1991) 841-846
30. Rispoli V., Rotiroti D., Carelli V., Liberatore F., Scipione L., and Marra R. Choline pivaloyl esters improve in rats cognitive and memory performances impaired by scopolamine treatment or lesions of the nucleus basalis of Meynert. Neurosci Lett 356 (2004) 199-202
31. Sabolek H.R., Bunce J.G., and Chrobak J.J. Intraseptal tacrine can enhance memory in cognitively impaired young rats. Neuroreport 5 (2004) 181-183
32. Sabolek H.R., Bunce J.G., and Chrobak J.J. Intraseptal tacrine-induced disruptions of spatial memory performance. Behav Brain Res 158 (2005) 1-7
33. Salmon L., Montet J.C., Oddoze C., Montet A.M., Portugal H., and Michel B.F. Ursodeoxycholic acid and prevention of tacrine-induced hepatotoxicity: a pilot study. Therapie 56 (2001) 29-34
34. Schildein S., Huston J.P., and Schwarting R.K. Injections of tacrine and scopolamine into the nucleus accumbens: opposing effects of immediate vs delayed posttrial treatment on memory of an open field. Neurobiol Learn Mem 73 (2000) 21-30
35. Schildein S., Huston J.P., and Schwarting R.K. Open field habituation learning is improved by nicotine and attenuated by mecamylamine administered posttrial into the nucleus accumbens. Neurobiol Learn Mem 77 (2002) 277-290
36. Stachlewitz R.F., Arteel G.E., Raleigh J.A., Connor H.D., Mason R.P., and Thurman R.G. Development and characterization of a new model of tacrine-induced hepatotoxicity: role of the sympathetic nervous system and hypoxia-reoxygenation. J Pharmacol Exp Ther 282 (1997) 1591-1599
37. Van Dam D., Hooge R.D., Staufenbiel M., Van Ginneken C., Van Meir F., and De Deyn P.P. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17 (2003) 388-396
38. Wagstaff A.J., and McTavish D. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 4 (1994) 510-540
39. Watkins P.B., Zimmerman H.J., Knapp M.J., Gracon S.I., and Lewis K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271 (1994) 992-998
40. Wang H., Carlier P.R., Ho W.L., Wu D.C., Lee N.T., Li C.P., et al. Effects of bis(7)-tacrine, a novel anti-Alzheimer's agent, on rat brain AChE. Neuroreport 10 (1999) 789-793
41. Zheng Q., Olivier K., Won Y.K., and Pope C.N. Comparative cholinergic neurotoxicity of oral chlorpyrifos exposures in preweanling and adult rats. Toxicol Sci 55 (2000) 124-132
42. Zheng J.Q., He X.P., Yang A.Z., and Liu C.G. Physostigmine blocked nicotinic acetylcholine receptors in rat sympathetic ganglion neurons. Acta Pharmacol Sin 18 (1997) 508-511
43. 3H]hemicholinium-3 bindin sites in rat neonate brain. Jpn J Pharmacol 84 (2000) 32-35